The latest announcement is out from BeiGene Ltd ( (HK:6160) ).
BeiGene, Ltd. has announced the availability of proxy materials on the U.S. Securities and Exchange Commission’s website as part of its regulatory compliance. This announcement reflects the company’s ongoing commitment to transparency and adherence to international regulatory standards, which may enhance its reputation and trust among stakeholders.
More about BeiGene Ltd
BeiGene, Ltd. is a biotechnology company focused on developing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company operates in the pharmaceutical industry and is committed to improving treatment outcomes for cancer patients worldwide.
YTD Price Performance: 49.18%
Average Trading Volume: 3,926,812
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$240.1B
For detailed information about 6160 stock, go to TipRanks’ Stock Analysis page.